NSG 552
PSYCHOPHARMACOLOGY
EXAMS | 2026/2027 VERIFIED
LATEST MOCK PRACTICE SET
240 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 552 PSYCHOPHARMACOLOGY EXAMS | 2026/2027 VERIFIED MCQS | AND ANSWERS WITH
RATIONALES | PMHNP CLINICAL KNOWLEDGE EXCELLENCE |ALREADY GRADED A+ |GUARANTEED
SUCCESS. It contains 240 carefully selected questions that reflect the most current exam content and testing
strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 240 Questions
Foundations - Application - NSG 552 Psychopharmacology Exams 2026/2027 MCQS AND WITH
Rationales Pmhnp Clinical Knowledge Excellence Already A Guaranteed Success Psychopharmacology
Graduate Pmhnp
All answers with rationales
,Table of Contents
Section A - Neurobiology AND Section B - Antidepressants AND
Neurotransmitters MOOD Stabilizers
Questions 1 to 60 Questions 61 to 120
Section C - Antipsychotics AND Section D - Anxiolytics AND
Movement Disorders Sedative-hypnotics
Questions 121 to 180 Questions 181 to 240
,Section A - Neurobiology AND Neurotransmitters
Q1.
A patient with treatment-resistant depression is being considered for augmentation with a
second-generation antipsychotic. Which of the following mechanisms best explains the
rapid improvement in depressive symptoms observed with low-dose aripiprazole
augmentation?
A. Antagonism of 5-HT2A receptors leading B. Partial agonism at D2 and 5-HT1A
to increased dopamine release in the receptors with functional selectivity
prefrontal cortex
C. Inhibition of serotonin and norepinephrine D. Antagonism of alpha-2 adrenergic
reuptake autoreceptors
Correct: B - Partial agonism at D2 and 5-HT1A receptors with functional selectivity
Rationale:Aripiprazole is a D2 and 5-HT1A partial agonist; its functional selectivity allows for
modulation of dopaminergic tone without full blockade, contributing to rapid antidepressant
effects. Option A describes a property of many atypical antipsychotics but not the primary
mechanism for aripiprazole's rapid effect. Option C describes SNRIs. Option D describes
mirtazapine.
Q2.
A patient with bipolar I disorder is stabilized on lithium but develops polyuria and
polydipsia. Urine osmolality after water deprivation is 300 mOsm/kg, and after
desmopressin is 310 mOsm/kg. Which of the following best explains this finding?
A. Impaired renal concentrating ability due B. Central diabetes insipidus due to lithium
to lithium-induced downregulation of suppression of antidiuretic hormone
aquaporin-2 channels secretion
C. Primary polydipsia with normal renal D. Lithium-induced interstitial nephritis
function causing nephrogenic diabetes insipidus
Correct: A - Impaired renal concentrating ability due to lithium-induced downregulation of
aquaporin-2 channels
Rationale:The water deprivation test shows inability to concentrate urine (300 mOsm/kg) and
no response to desmopressin (310 mOsm/kg), indicating nephrogenic diabetes insipidus.
Lithium enters collecting duct cells via ENaC, inhibits glycogen synthase kinase-3, and
reduces aquaporin-2 expression, impairing water reabsorption. Option B describes central DI
which would respond to desmopressin. Option C would show normal concentrating ability
after deprivation. Option D is a chronic effect but not the acute mechanism.
Page 3
, Section A - Neurobiology AND Neurotransmitters
Q3.
Which of the following pharmacodynamic interactions is most likely to result in serotonin
syndrome when combining a monoamine oxidase inhibitor (MAOI) with a selective
serotonin reuptake inhibitor (SSRI)?
A. Synergistic inhibition of CYP2D6 leading B. Additive inhibition of serotonin reuptake
to increased SSRI levels and metabolism
C. MAOI-induced increase in serotonin D. MAOI-mediated inhibition of monoamine
release combined with SSRI blockade of oxidase in the gut and liver reducing
reuptake first-pass metabolism of SSRI
Correct: B - Additive inhibition of serotonin reuptake and metabolism
Rationale:Serotonin syndrome results from excessive serotonergic activity. MAOIs
irreversibly inhibit monoamine oxidase, preventing serotonin breakdown, while SSRIs block
reuptake, leading to intrasynaptic serotonin accumulation. Option A describes a
pharmacokinetic interaction that could contribute but is not the primary mechanism. Option C
is inaccurate because MAOIs do not directly increase serotonin release. Option D describes a
pharmacokinetic effect on tyramine, not serotonin.
Q4.
A patient on clozapine develops fever, tachycardia, and fluctuating consciousness. Lab
results show leukocytosis and elevated creatine kinase. Which of the following is the most
appropriate next step?
A. Discontinue clozapine immediately and B. Reduce clozapine dose and add a
initiate supportive care benzodiazepine
C. Start antibiotics and continue clozapine D. Administer dantrolene and continue
clozapine
Correct: A - Discontinue clozapine immediately and initiate supportive care
Rationale:The presentation suggests neuroleptic malignant syndrome (NMS) or
clozapine-induced myocarditis. Clozapine must be discontinued immediately due to risk of
fatal complications. Option B is inappropriate because reducing dose may not halt
progression. Option C is incorrect unless infection is confirmed. Option D (dantrolene) is used
for malignant hyperthermia, not first-line for NMS; clozapine should be stopped.
Q5.
A patient with generalized anxiety disorder has been on sertraline 200 mg daily for 8
weeks with partial response. Which of the following evidence-based strategies is most
appropriate?
Page 4
PSYCHOPHARMACOLOGY
EXAMS | 2026/2027 VERIFIED
LATEST MOCK PRACTICE SET
240 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 552 PSYCHOPHARMACOLOGY EXAMS | 2026/2027 VERIFIED MCQS | AND ANSWERS WITH
RATIONALES | PMHNP CLINICAL KNOWLEDGE EXCELLENCE |ALREADY GRADED A+ |GUARANTEED
SUCCESS. It contains 240 carefully selected questions that reflect the most current exam content and testing
strategies. Each question is accompanied by a correct answer and a detailed rationale that explains the
underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 240 Questions
Foundations - Application - NSG 552 Psychopharmacology Exams 2026/2027 MCQS AND WITH
Rationales Pmhnp Clinical Knowledge Excellence Already A Guaranteed Success Psychopharmacology
Graduate Pmhnp
All answers with rationales
,Table of Contents
Section A - Neurobiology AND Section B - Antidepressants AND
Neurotransmitters MOOD Stabilizers
Questions 1 to 60 Questions 61 to 120
Section C - Antipsychotics AND Section D - Anxiolytics AND
Movement Disorders Sedative-hypnotics
Questions 121 to 180 Questions 181 to 240
,Section A - Neurobiology AND Neurotransmitters
Q1.
A patient with treatment-resistant depression is being considered for augmentation with a
second-generation antipsychotic. Which of the following mechanisms best explains the
rapid improvement in depressive symptoms observed with low-dose aripiprazole
augmentation?
A. Antagonism of 5-HT2A receptors leading B. Partial agonism at D2 and 5-HT1A
to increased dopamine release in the receptors with functional selectivity
prefrontal cortex
C. Inhibition of serotonin and norepinephrine D. Antagonism of alpha-2 adrenergic
reuptake autoreceptors
Correct: B - Partial agonism at D2 and 5-HT1A receptors with functional selectivity
Rationale:Aripiprazole is a D2 and 5-HT1A partial agonist; its functional selectivity allows for
modulation of dopaminergic tone without full blockade, contributing to rapid antidepressant
effects. Option A describes a property of many atypical antipsychotics but not the primary
mechanism for aripiprazole's rapid effect. Option C describes SNRIs. Option D describes
mirtazapine.
Q2.
A patient with bipolar I disorder is stabilized on lithium but develops polyuria and
polydipsia. Urine osmolality after water deprivation is 300 mOsm/kg, and after
desmopressin is 310 mOsm/kg. Which of the following best explains this finding?
A. Impaired renal concentrating ability due B. Central diabetes insipidus due to lithium
to lithium-induced downregulation of suppression of antidiuretic hormone
aquaporin-2 channels secretion
C. Primary polydipsia with normal renal D. Lithium-induced interstitial nephritis
function causing nephrogenic diabetes insipidus
Correct: A - Impaired renal concentrating ability due to lithium-induced downregulation of
aquaporin-2 channels
Rationale:The water deprivation test shows inability to concentrate urine (300 mOsm/kg) and
no response to desmopressin (310 mOsm/kg), indicating nephrogenic diabetes insipidus.
Lithium enters collecting duct cells via ENaC, inhibits glycogen synthase kinase-3, and
reduces aquaporin-2 expression, impairing water reabsorption. Option B describes central DI
which would respond to desmopressin. Option C would show normal concentrating ability
after deprivation. Option D is a chronic effect but not the acute mechanism.
Page 3
, Section A - Neurobiology AND Neurotransmitters
Q3.
Which of the following pharmacodynamic interactions is most likely to result in serotonin
syndrome when combining a monoamine oxidase inhibitor (MAOI) with a selective
serotonin reuptake inhibitor (SSRI)?
A. Synergistic inhibition of CYP2D6 leading B. Additive inhibition of serotonin reuptake
to increased SSRI levels and metabolism
C. MAOI-induced increase in serotonin D. MAOI-mediated inhibition of monoamine
release combined with SSRI blockade of oxidase in the gut and liver reducing
reuptake first-pass metabolism of SSRI
Correct: B - Additive inhibition of serotonin reuptake and metabolism
Rationale:Serotonin syndrome results from excessive serotonergic activity. MAOIs
irreversibly inhibit monoamine oxidase, preventing serotonin breakdown, while SSRIs block
reuptake, leading to intrasynaptic serotonin accumulation. Option A describes a
pharmacokinetic interaction that could contribute but is not the primary mechanism. Option C
is inaccurate because MAOIs do not directly increase serotonin release. Option D describes a
pharmacokinetic effect on tyramine, not serotonin.
Q4.
A patient on clozapine develops fever, tachycardia, and fluctuating consciousness. Lab
results show leukocytosis and elevated creatine kinase. Which of the following is the most
appropriate next step?
A. Discontinue clozapine immediately and B. Reduce clozapine dose and add a
initiate supportive care benzodiazepine
C. Start antibiotics and continue clozapine D. Administer dantrolene and continue
clozapine
Correct: A - Discontinue clozapine immediately and initiate supportive care
Rationale:The presentation suggests neuroleptic malignant syndrome (NMS) or
clozapine-induced myocarditis. Clozapine must be discontinued immediately due to risk of
fatal complications. Option B is inappropriate because reducing dose may not halt
progression. Option C is incorrect unless infection is confirmed. Option D (dantrolene) is used
for malignant hyperthermia, not first-line for NMS; clozapine should be stopped.
Q5.
A patient with generalized anxiety disorder has been on sertraline 200 mg daily for 8
weeks with partial response. Which of the following evidence-based strategies is most
appropriate?
Page 4
